Intestinal Research

Review

IBD

Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition: Filiz Akyüz, Yoon Kyo An, Jakob Begun, Satimai Aniwan, Huu Hoang Bui, Webber Chan, Chang Hwan Choi, Nazeer Chopdat, Susan J Connor, Devendra Desai, Emma Flanagan, Taku Kobayashi, Allen Yu-Hung Lai, Rupert W Leong, Alex Hwong-Ruey Leow, Wai Keung Leung, Julajak Limsrivilai, Virly Nanda Muzellina, Kiran Peddi, Zhihua Ran, Shu Chen Wei, Jose Sollano, Michelle Mui Hian Teo, Kaichun Wu, Byong Duk Ye, Choon Jin Ooi; Intest Res 2025;23(1):37-55. Published online November 4, 2024; DOI: https://doi.org/10.5217/ir.2024.00089

The lack of clear definition and classification for “moderate ulcerative colitis (UC)” creates ambiguity regarding the suitability of step-up versus top-down treatment approaches. In this paper, experts address crucial gaps in assessing and managing moderate UC. The Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition comprised 24 experts who convened to share, discuss and vote electronically on management recommendations for moderate UC. Experts emphasized that the goal of treating UC is to attain clinical, biomarker, and endoscopic remission using cost-effective strategies such as 5-aminosalicylates (5-ASAs), well-tolerated therapy that can be optimized to improve outcomes. Experts agreed that 5-ASA therapy could be optimized by maximizing dosage (4 g/day for induction of remission), combining oral and topical administration, extending treatment duration beyond 8 weeks, and enhancing patient adherence through personalized counselling and reduced pill burden. Treatment escalation should ideally be reserved for patients with predictors of aggressive disease or those who do not respond to 5-ASA optimization. Premature treatment escalation to advanced therapies (including biologics and oral small molecules) may have long-term health and financial consequences. This paper provides consensus-based expert recommendations and a treatment algorithm, based on current evidence and practices, to assist decision-making in real-world settings.

Citations

Citations to this article as recorded by

CU104, a novel barrier function enhancer, improves colitis via modulation of barrier function and immune cell recruitment
I Seul Park, Ji Hyung Kim, Dongyeop Kim, Ye Won Kim, Yoojin Shin, Ki Beom Kim, Haiying Zhang, Tae Il Kim, Seung Won Kim, Young-Guen Kwon, Jae Hee Cheon
Frontiers in Immunology.2026;[Epub] CrossRef
Dosing 5-ASA for Ulcerative Colitis: Is the Maximum Optimum?
Nai-Yu Chen, Chiao-Hsiung Chuang
Digestive Diseases and Sciences.2026;[Epub] CrossRef
Therapeutic Promise of the Panax Genus in Ulcerative Colitis: Unraveling the Multitarget Mechanisms of Saponins and Polysaccharides
Cailan Li, Yi Zhou, Yuanqi Jiao, Xingfang Qian, Xuefei Wang, Haohui Chen, Luyou Zhao, Han Zhang, Qiang Lu
Journal of Agricultural and Food Chemistry.2026; 74(16): 12569. CrossRef
Oral Colon-Targeted Lipid Nanoparticles Enhance Upadacitinib Delivery and Efficacy in a Murine Model of Ulcerative Colitis
Rabeya Jafrin Mow, Xiaodi Shi, Wen Lu, Siming Wang, Didier Merlin, Chunhua Yang
International Journal of Molecular Sciences.2026; 27(9): 3758. CrossRef
Inflammatory bowel disease in Africa: the current landscape of pharmacological treatments and the promise of emerging innovations
Murtada A. Oshi
Exploration of Drug Science.2025;[Epub] CrossRef

22,248 View
419 Download
5 Web of Science
5 Crossref

First
Prev
Page of 1
Next
Last

Search